The partnership will include collaborative research with a focus on expanding the use of in vitro diagnostics to support antimicrobial stewardship programs.

NEW YORK – The Alzheimer's Drug Discovery Foundation on Wednesday announced that it has invested $7.0 million in Alzheimer's disease diagnostic company C2N Diagnostics. Already have a 360Dx or ...

Trinity plans to bring to market in 2025 Metabolomics Diagnostics' PrePsia test that can be used to determine preeclampsia risk in the 12th week of pregnancy.

NEW YORK – Fujirebio said Wednesday that its subsidiary Fujirebio Diagnostics has filed its Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio in vitro diagnostic with the US Food and Drug ...

The national contract covers FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne RNA, and FoundationOne Heme.

The tool uses two blood-based biomarkers and up to five clinical features to generate a risk score for prostate cancer aggressiveness.

The change applies to qualitative and quantitative hepatitis B virus antigen, antibody, and nucleic acid assays that are used to detect acute and chronic infections.

The agreement includes $650 million of 4.35 percent senior notes, $500 million of 4.55 percent senior notes, and $850 million of 4.8 percent senior notes.

The letter encourages drug developers to "further study and use" αSyn-SAA testing for selecting patients for clinical trials for Parkinson's and related diseases.

The drop represents a return to a more normal pace of openings post-pandemic but likely also reflects the reimbursement and regulatory challenges facing the industry.

Quest will become the exclusive independent national laboratory provider of clinical lab and anatomic pathology services for Sentara members in Florida and Virginia.